[Circulating serum STN antigen as a prognostic marker in epithelial ovarian cancer].
Circulating serum sialyl Tn (STN) antigen levels were measured in 89 patients with epithelial ovarian cancer. Survival at 5 years for patients with STN-negative (serum STN levels less than 50 U/ml) versus STN-positive tumors (serum STN levels greater than or equal to 50 U/ml) was 76.9% versus 10.8%, respectively (p less than 0.05). The overall survival probability was worse in patients with STN-positive sera. Percent progression-free survival at 5 years for patients with STN-negative versus STN-positive tumors was 51.9% versus 5.4%, respectively (p less than 0.05). The overall progression-free survival was shorter in patients with STN-positive sera. Multivariate regression analysis revealed that positive STN antigen level in sera is an independent predictor of poor prognosis in epithelial ovarian cancer.
Dept. of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Japan.
H
H
Kobayashi
T
T
Terao
Y
Y
Kawashima
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D016256:Lewis X Antigen / Q000097:blood*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology / Q000401:mortality*; D011379:Prognosis; D016016:Proportional Hazards Models; D015996:Survival Rate
D014408:Biomarkers, Tumor; D016256:Lewis X Antigen